novo nordisk's semaglutide failed to slow alzheimer's disease progression Nordisk shares slide after Ozempic pill fails in trials | Pharmaceuticals industry glp1 #drugdevelopment #clinicaldevelopment #alzheimersdisease #alzheimersresearch

The FDAs primary enforcement mechanism is against vendors who make explicit health claims or market compounds as supplements or medicines

GLP2 versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial

doi: 10.3389/fpsyt.2021.671151 Received 23 February 2021 Accepted 02 September 2021 Published 30 September 2021 Volume 12 - 2021 Edited by Agorastos Agorastos, Aristotle University of Thessaloniki, Greece Reviewed by Carla Nasca, The Rockefeller University, United States

Long-term safety data simply does not exist for either peptide in humans

Sci Adv (2017) 3(6):e1602025.10.1126/sciadv.1602025 114 TilbrookPAIngleyEWilliamsJHHibbsMLKlinkenSP

Besides weight loss, Ozempic offers other health benefits, including improved diabetes control, kidney function, and cardiovascular health